Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2017

17.08.2017 | Retinal Disorders

Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy

verfasst von: Eui Chun Kang, Seonghee Choi, Hyoung Jun Koh

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate predictive factors for changes in best-corrected visual acuity (BCVA) at 24 months after intravitreal ranibizumab (IVR) for neovascular age-related macular degeneration (nAMD).

Methods

This retrospective study included 55 eyes of 55 consecutive patients (32 men and 23 women) with nAMD who received three consecutive monthly IVR injections and were re-treated as needed over a 24-month period. We used the mean changes in logarithm of the minimal angle of resolution (logMAR) BCVA at 24 months as the dependent variable in regression analysis.

Results

The presence of intraretinal cystoid spaces in the inner nuclear layer (INLc, P = 0.004) and baseline subfoveal choroidal thickness (SFCT, P = 0.013) predicted BCVA changes from baseline to 24 months. The presence of INLc and thinning of SFCT were associated with decreased BCVA at 24 months. Thirty-five eyes without INLc showed improved logMAR BCVA, from 0.550 ± 0.273 to 0.368 ± 0.274 (P = 0.045); however, 20 eyes with INLc showed decreased logMAR BCVA, from 0.708 ± 0.347 to 0.971 ± 0.523 (P < 0.001) through the 24-month follow-up. The mean number of IVR injections during the follow-up period was 8.74 ± 4.76 in eyes without INLc and 10.63 ± 4.72 in eyes with INLc, without a statistically significant difference (P = 0.144).

Conclusion

Eyes with INLc or thinned SFCT showed worse visual outcomes compared with eyes without the INLc or with thick SFCT. Furthermore, eyes without INLc showed improved BCVA; however, eyes with INLc showed decreased BCVA with an as-needed regimen.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293CrossRefPubMed Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293CrossRefPubMed
2.
Zurück zum Zitat Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH (2013) Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 37:182–199CrossRefPubMed Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH (2013) Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 37:182–199CrossRefPubMed
3.
Zurück zum Zitat Wolf A, Kampik A (2014) Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 252:647–655CrossRefPubMedPubMedCentral Wolf A, Kampik A (2014) Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 252:647–655CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728–1738CrossRefPubMed Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728–1738CrossRefPubMed
5.
Zurück zum Zitat Miller JW (2013) Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol 155:1-35.e13 Miller JW (2013) Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol 155:1-35.e13
6.
Zurück zum Zitat Kodjikian L, Decullier E, Souied EH, Girmens JF, Durand EE, Chapuis FR, Huot L (2014) Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefes Arch Clin Exp Ophthalmol 252:1529–1537CrossRefPubMedPubMedCentral Kodjikian L, Decullier E, Souied EH, Girmens JF, Durand EE, Chapuis FR, Huot L (2014) Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefes Arch Clin Exp Ophthalmol 252:1529–1537CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258–1267CrossRefPubMed Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258–1267CrossRefPubMed
8.
Zurück zum Zitat Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398CrossRefPubMedPubMedCentral Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152CrossRefPubMed Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152CrossRefPubMed
10.
Zurück zum Zitat Spaide RF (2009) The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 148:1–3CrossRefPubMed Spaide RF (2009) The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 148:1–3CrossRefPubMed
11.
Zurück zum Zitat Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 31:26–30CrossRefPubMed Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 31:26–30CrossRefPubMed
12.
Zurück zum Zitat Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2015) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. doi:10.1136/bjophthalmol-2015-306987 Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2015) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. doi:10.​1136/​bjophthalmol-2015-306987
13.
Zurück zum Zitat Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR (2015) Prospective trial of treat-and-extend versus monthly dosing for Neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514–2522CrossRefPubMed Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR (2015) Prospective trial of treat-and-extend versus monthly dosing for Neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514–2522CrossRefPubMed
14.
Zurück zum Zitat Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD (2015) Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 159:3–8.e1CrossRefPubMed Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD (2015) Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 159:3–8.e1CrossRefPubMed
15.
Zurück zum Zitat Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303–2310CrossRefPubMed Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303–2310CrossRefPubMed
16.
Zurück zum Zitat Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG (2016) Outcomes in eyes with retinal Angiomatous proliferation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 123:609–616CrossRefPubMed Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG (2016) Outcomes in eyes with retinal Angiomatous proliferation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 123:609–616CrossRefPubMed
17.
Zurück zum Zitat Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T (2014) Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 132:1317–1326CrossRefPubMed Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T (2014) Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 132:1317–1326CrossRefPubMed
18.
Zurück zum Zitat Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94:e757–e764CrossRefPubMed Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94:e757–e764CrossRefPubMed
19.
Zurück zum Zitat Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: a literature review and consensus recommendations. Retina 35:1489–1506CrossRefPubMed Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: a literature review and consensus recommendations. Retina 35:1489–1506CrossRefPubMed
20.
Zurück zum Zitat Schmidt-Erfurth U, Waldstein SM (2016) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1–24CrossRefPubMed Schmidt-Erfurth U, Waldstein SM (2016) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1–24CrossRefPubMed
21.
Zurück zum Zitat Sulzbacher F, Roberts P, Munk MR, Kaider A, Kroh ME, Sacu S, Schmidt-Erfurth U (2015) Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept. Invest Ophthalmol Vis Sci 56:1158–1167CrossRef Sulzbacher F, Roberts P, Munk MR, Kaider A, Kroh ME, Sacu S, Schmidt-Erfurth U (2015) Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept. Invest Ophthalmol Vis Sci 56:1158–1167CrossRef
22.
Zurück zum Zitat Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM (2014) Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 121:1237–1245CrossRefPubMed Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM (2014) Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 121:1237–1245CrossRefPubMed
23.
Zurück zum Zitat Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22CrossRefPubMed Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22CrossRefPubMed
24.
Zurück zum Zitat Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C (2015) Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 122:822–832CrossRefPubMed Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C (2015) Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 122:822–832CrossRefPubMed
25.
Zurück zum Zitat Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ (2016) Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:865–875CrossRefPubMedPubMedCentral Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ (2016) Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:865–875CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U (2016) Predictive value of retinal morphology for visual acuity outcomes of different Ranibizumab treatment regimens for Neovascular AMD. Ophthalmology 123:60–69CrossRefPubMed Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U (2016) Predictive value of retinal morphology for visual acuity outcomes of different Ranibizumab treatment regimens for Neovascular AMD. Ophthalmology 123:60–69CrossRefPubMed
27.
Zurück zum Zitat Antcliff RJ, Hussain AA, Marshall J (2001) Hydraulic conductivity of fixed retinal tissue after sequential excimer laser ablation: barriers limiting fluid distribution and implications for cystoid macular edema. Arch Ophthalmol 119:539–544CrossRefPubMed Antcliff RJ, Hussain AA, Marshall J (2001) Hydraulic conductivity of fixed retinal tissue after sequential excimer laser ablation: barriers limiting fluid distribution and implications for cystoid macular edema. Arch Ophthalmol 119:539–544CrossRefPubMed
28.
Zurück zum Zitat Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232CrossRefPubMed Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232CrossRefPubMed
29.
Zurück zum Zitat Marmor MF (1999) Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 97:239–249CrossRefPubMed Marmor MF (1999) Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 97:239–249CrossRefPubMed
30.
Zurück zum Zitat Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30:1333–1349CrossRefPubMed Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30:1333–1349CrossRefPubMed
31.
Zurück zum Zitat Biesemeier A, Taubitz T, Julien S, Yoeruek E, Schraermeyer U (2014) Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging 35:2562–2573CrossRefPubMed Biesemeier A, Taubitz T, Julien S, Yoeruek E, Schraermeyer U (2014) Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging 35:2562–2573CrossRefPubMed
32.
Zurück zum Zitat Berenberg TL, Metelitsina TI, Madow B, Dai Y, Ying GS, Dupont JC, Grunwald L, Brucker AJ, Grunwald JE (2012) The association between drusen extent and foveolar choroidal blood flow in age-related macular degeneration. Retina 32:25–31CrossRefPubMedPubMedCentral Berenberg TL, Metelitsina TI, Madow B, Dai Y, Ying GS, Dupont JC, Grunwald L, Brucker AJ, Grunwald JE (2012) The association between drusen extent and foveolar choroidal blood flow in age-related macular degeneration. Retina 32:25–31CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Whitmore SS, Sohn EH, Chirco KR, Drack AV, Stone EM, Tucker BA, Mullins RF (2015) Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res 45:1–29CrossRefPubMed Whitmore SS, Sohn EH, Chirco KR, Drack AV, Stone EM, Tucker BA, Mullins RF (2015) Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res 45:1–29CrossRefPubMed
34.
Zurück zum Zitat Sohn EH, Khanna A, Tucker BA, Abramoff MD, Stone EM, Mullins RF (2014) Structural and biochemical analyses of choroidal thickness in human donor eyes. Invest Ophthalmol Vis Sci 55:1352–1360CrossRefPubMedPubMedCentral Sohn EH, Khanna A, Tucker BA, Abramoff MD, Stone EM, Mullins RF (2014) Structural and biochemical analyses of choroidal thickness in human donor eyes. Invest Ophthalmol Vis Sci 55:1352–1360CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540–546CrossRefPubMed Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540–546CrossRefPubMed
36.
Zurück zum Zitat Rakic JM, Leys A, Brie H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, Macdonald K, Abraham I (2013) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 7:1849–1858PubMedPubMedCentral Rakic JM, Leys A, Brie H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, Macdonald K, Abraham I (2013) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 7:1849–1858PubMedPubMedCentral
37.
Zurück zum Zitat Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, Schneider V (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33:474–481CrossRefPubMed Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, Schneider V (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33:474–481CrossRefPubMed
38.
Zurück zum Zitat Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226CrossRefPubMed Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226CrossRefPubMed
39.
Zurück zum Zitat Tufail A, Xing W, Johnston R, Akerele T, McKibbin M, Downey L, Natha S, Chakravarthy U, Bailey C (2014) The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121:1092–1101CrossRef Tufail A, Xing W, Johnston R, Akerele T, McKibbin M, Downey L, Natha S, Chakravarthy U, Bailey C (2014) The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121:1092–1101CrossRef
40.
Zurück zum Zitat Chong V (2016) Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 30:270–286CrossRef Chong V (2016) Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 30:270–286CrossRef
41.
Zurück zum Zitat Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CM (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139CrossRefPubMed Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CM (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139CrossRefPubMed
Metadaten
Titel
Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy
verfasst von
Eui Chun Kang
Seonghee Choi
Hyoung Jun Koh
Publikationsdatum
17.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2017
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3776-9

Weitere Artikel der Ausgabe 11/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.